Early thymocytes undergo extensive proliferation after their entry into the thymus, but cellular interactions and cytokines regulating this intrathymic step remain t o be determined. We analyzed the effects of various T-cell growth factors and cellular interactions on in vitro proliferation of early CD2'CD3/TCR-CD4-CD8-(triple negative [TN]) human thymocytes. Freshly isolated TN cells were then assayed for their growth capacity after incubation with CD21,111-monoclonal antibody (MoAb), recombinant human interleukin-2 (IL-21. IL-7, and/or IL-4. These cells displayed significant proliferative responses with IL-4, IL-7, or CD2-MoAb+lL-2. The addition of recombinant transforming Recently, TGFP from thymic epithelial cells was shown to play a role in murine T-cell maturation.'' However, the role of TGFPl on early human T-cell proliferation was not clearly determined. T-cell differentiation occurs in the thymus where bone marrow-derived prothymocytes develop into cells expressing TCWCD3, a prerequisite event for their subsequent selection and function.14"* The first human intrathymic step is characterized by an extensive growth of early prec~rsors,'"'~ whereas the role of soluble growth factors 0006-4971/95/8512-0030$3.00/0 3594 sensitive to growth inhibition. We thus asked whether the CD8+ cell-derived inhibitory effect was due t o TGFp. The addition of neutralizing anti-TGFP MoAb completely abolished CD8' cell-derived inhibition of TN cell growth. Analysis of CD8+ cell-derived supernatants indicated that these cells had IOW TGFPl production capacity, whereas TN cells secrete significantly high levels of TGFP1. Cell fixation studies showed that TN cells were the source of the TGFP. TGFpl released from TN cells was in the latent form that became the active inhibitory form through interaction of TN cells with CD8' cells. Together, these data suggest a role for TGFPl as an externally controlled, autocrine inhibaory factor for human early thymocytes, with a regulatory role in thymic T-cell output.
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and cell-cell interactions between various thymic cell subsets in this phenomenon remain to be determined. In vitro, normal unfractionated thymocytes respond poorly to mitogens or antigens." Extensive programmed cell abnormal signal transduction capacity of double-positive cells (CD4.+CD8+) after ligation of CD3 or CD2 antigen^,'^,'^ and a role for suppressor cells2" have been suggested to explain this phenomenon. By contrast to CD3+CD4+CD8+ thymocytes, human triple-negative (TN) cells (CD3-CD4-CD8-) possess comparatively higher proliferative capacity in vitro4.s.x.12 and have the potential to generate CD3/TCR+ cells after appropriate in vitro c~n d i t i o n i n g . '~" *~~~~~* In vitro proliferation of these precursors can be observed following their treatment with IL-7, IL-2, or IL-4. These cytokines are well known as the most common physiologic growth factors for T-cell lineage, including leukemic precursor ce11s.18.19~24~29 This report shows an important inhibitory effect of TGFPl and autologous CD8+CD4-cells on early TN cell proliferation. TGFPl is also shown to be secreted by early thymocytes and accounts for the inhibitory effect of CD8+ cells. , and polyclonal anti-TNFa antibody (Tebu). All human sera used were pretested to ensure that there were no inhibitory effects on thymocyte proliferation. Tritiated thymidine (1 pCi/well; CEA, Les Ulis, France) was incorporated at day 4 and radioactivity uptake was measured 18 hours later. Maximal growth responses were observed after this incubation period, as suggested by our previous ~tudy.'~.'~ TGFPI was quantified using a specific radioimmunoassay (NENDupont, Paris, France) as recommended by the manufacturer. This assay detects more than 30 pg TGFPl in cell supernatants and measures active as well as latent TGFP. For some experiments the cells were irradiated with 3,000 rad or fixed with paraformaldehyde before cultures.
Statistics. Various results were analyzed and compared using the Student's t-test for paired data.
RESULTS

Definition of growth requirement of TN early thymocytes.
TN thymocytes were assayed for their proliferative response after their incubation with comitogenic CD21+III-M~Abr CD3-MoAb, IL-2, IL-7, and/or IL-4 and compared with other major thymocyte subsets. Optimal concentrations of these reagents were previously Results in Table 2 indicate that thymocytes varied in their response to the above physiologic signals. Double-positive (CD4+CD8+) and unfractionated thymocytes displayed significantly lower growth ability than other thymic cell subsets ( P < .001; Table 2 ). TN thymocytes, as predicted from their surface phenotype (Table l) Recombinant TGFPl was therefore added to early thymocytes cultured in the presence of CD2-MoAb+IL-2, IL-7, or IL-4. A dose-dependent inhibition of the proliferative responses was observed (Fig l) , which indicates that TGFPl displays a high inhibitory effect on E-2-or IL-7-dependent thymocytes growth ( P < .001), whereas IL-4-dependent TN cell proliferation was less sensitive to TGFPl addition (P < .05). This finding indicates that these cytokines induced distinct proliferation pathways in human early thymocytes. TGFP effect can be reversed through the addition of neutralizing anti-TGFP MoAb to the cultures but not through the addition of an isotype-matched control (CD19-MoAb; Fig 1) .
Mature CD8+ thymocytes downregulate the proliferation of TN thymocytes. Cellular interactions regulating early thymocyte growth remain ill defined. However, we have previously shown that agar colony formation by prothymocytes was inhibited by CD8+4-thymic subset." We assayed here the effect of CD8+ as well as other major thymic cell subsets on the growth of TN cells stimulated with CD2-MoAb+IL-2. Data in Fig 2 show the ability of CD8' cells to inhibit the proliferation of TN thymocytes ( P .007) in a dose-dependent manner, whereas TN, CD4+, and CD4+CD8' cell subsets displayed no such inhibitory effect. Higher amounts of exogenous IL-2 (500 to 1, OOO U / d ) or CD2-MoAb (up to 100 pg/mL) did not significantly overcome this inhibitory effect (not shown). This finding indicated that the CD8' cell-derived effect was not caused by IL-2 or CD2-MoAb consumption.
by CD2-MoAb. Thymocyte subsets were incubated (lO'/lOO pUwell) with rlL-2 (100 U/mL), CD3 MoAb (20 pg/mL), comitogenic CD~MII-MOA~ (V400 ascites from each), rlL-7 (10 ng/mL), and rlL-4 (10 ng/mL). Tritiated thymidine was added at day 4 and radioactivity uptake was measured 18 hours later. Results represent the mean values from nine distinct thymocyte preparations, each performed in triplicate (SE <11%).
Abbreviation: NT, not tested.
Phenohpical characterization of downregulating CD8'
cells. The data above led us to investigate the surface phenotype of the suppressor CD8' cells. CD2TD8' thymocytes are a heterogeneous cell population and contain the precursors of functionally distinct peripheral T lymphocyte~.'~"' Using negative selection procedure (by positive cell elimination), we attempted to further define the cell subset responsible for the inhibition of TN cell proliferation. CD8' cells were therefore treated with CD3-, CD4-, CD57-, or D44-MoAb; negative cells were then sorted and assayed for their suppressive activity. After treatment with above MoAb, CD8' cells contained less than 2% cell positivity with the MoAb used for cell elimination. D44 MoAb was used because it was previously described to recognize functionally distinct peripheral blood CD8' cell subsets: CD8'D44' cells are mostly cytotoxic, whereas CD8'DUlymphocytes comprise cells that suppress Ig secretion by B lymphocytes.3' Although a minor subset of CD8' cells (2% to 4%), CD44' cells were also sorted and assayed in this study. Data in Fig 3A show the effect of various cell depletions on the ability of CD8' cells to suppress the proliferation of TN cells. CD4'. CD57'.
or D44' cell depletion from CD8' cells did not affect their inhibitory effect, whereas CD3' cell elimination completely abolished CD8' cell-derived effect. These findings indicate that the suppressor cells are likely to be CD3'CD8+CD4-CD57-DU-. Consequently, we have positively sorted these cells (2% to 4% total thymocytes) and assayed them for their ability to suppress TN cell growth. Data in Fig 3B confirm the high inhibitory effect of both irradiated and nonirradiated CD8' cells on both IL-2-and IL-7-mediated proliferation of TN cells and indicate that suppression was not caused by CD8' cell irradiation. Together, these data clearly show that CD3TD8' thymocytes comprise cells that downregulate the proliferation of TN thymocytes.
Anti-TGFpl MoAh reverses CD8' cell-derived inhibiton effects. To clarify the mechanism of CD8'
cell-derived suppression, we first asked whether an inhibitory cytokine was involved in this phenomenon. In regard to the similarities between CD8' cell-derived and TGFPI-derived effects, we have analyzed the role of TGFPl in CD8' cell-derived inhibition of TN cell proliferation. TN thymocytes were then cultured in the presence of CD2-MoAb+IL-2. irradiated CD8' cells, neutralizing anti-TGFPI MoAb, anti-TNFa Ab, andor an isotype-matched control (IOB4). Interestingly, only anti-TGFPI addition to these cocultures significantly reversed the inhibitory effect of CD8' cells ( P < .001; Fig   4A) . This effect was dose-dependent and was not observed with control isotype-matched MoAb (Fig 4B) .
Human TN thymocytes produce high TGFPl levels. The effects of recombinant TGFPl on TN cell growth and the ability of anti-TGFP1 MoAb to reverse the inhibitory effect of CD8' cells led us to quantify the TGFPI levels produced by these cells as well as other thymic subsets. Unexpectedly, CD8' cells were poor producers of TGFPl (<0.8 ng/mL), even after their in vitro activation ( Table 3) . By contrast, TN thymocytes produced significantly high TGFPl levels, as did activated CD4' cells. However, this TGFPl was not active because these cells proliferated in vitro in the presence of the same growth factors (Table 2) . Finally, we have obtained similar data from three different TN cell preparations containing, respectively, 95%, 97%, and 99% CD2' cells, which suggest that contaminating non-T cells may not account for TGFPl production. Figure 5 shows that TGFPl production is dependent on TN cell numbers added to the cultures. These data indicate that TN thymocytes differ from other thymic subsets in their high TGFPl releasing capacity in the absence of apparent in vitro activation.
Meckanism of CD8' cell-derived inhibition of early tkymocyte prol(feration: role for TGFPI. We here analyzed the mechanism by which CD8' cells mediate the inhibitory effect on TN cells. In contrast to the cells themselves, the addition of CD8' cell supernatants had no effect on IL-2-or IL-7-dependent early thymocyte growth (Table 4 ). This finding indicates that these cells did not produce biologically active TGFPI. Because supernatants from cocultures of CD8' and TN cells displayed important inhibitory effect (Table 4) , we thus analyzed the role of each cell subset in inhibitory factor production. CD8' or TN thymocytes were then fixed by paraformaldehyde and cocultured with the other subset. As shown in Table 4 , CD8' cell fixation did not affect TN growth inhibition, whereas TN cell fixation completely abolished the release of the suppressor factor in these cocultures. CD8' cell addition to TN cell supernatants also converted from inactive to active TGFPI, which then inhibited TN cell growth. Incubation of TN-SN with CD8' cells did not significantly increase TGFPl levels, as measured by radioimmunoassay (data not shown). Finally. the suppressor effect of CD8' + TN cell-derived supernatants was reversed through the addition of anti-TGFPI MoAb (Table 4) . Together, these data indicate that TN cells are indeed the source of TGFPl that is converted to an active form after their interaction with CD8' cells. Values are the mean from three distinct thvmuses (SD < 13%).
emerged from these data. ( I ) Human thymocytes differ in their proliferation potential and sensitivity to IL-2, IL-7, and IL-4, which may be related to their developmental stages. (2) The growth of human TN thymocytes is downregulated Values are TGFBl levels quantified by radioimmunoassay in 48-hour supernatants from various thymocyte subsets. Values reflect representative data from one experiment (SD <15%) of three. The role of TGFP on human early T-cell development remains to be defined. The intrathymic sojourn of T lymphocytes constitutes an essential step in the generation of immunocompetent cells. Bone marrow prothymocytes migrate through the thymus, where they undergo extensive expansion together with the acquirement of various surface antigens including CD3/TCR.'"" These events allow subsequent positive and negative selection of appropriate clones. Present work shows that, although heterogeneou~,'~"~ early CD3-CD4-CD8-(TN) thymocytes display a significantly higher proliferation potential than most thymic cells ( Table  2 ). The absence of their response through CD3 cross-linking further confirmed the CD3-phenotype of these cells (Tables  1 and 2 ). High growth potential of TN thymocytes correlates with the fact that they belong to the proliferative compartment of thymic outer cortex.I5 In vivo, early thymocyte activation may be initiated through CD2-triggering by LFA-3 antigen on epithelial cell^.'"^^.^^ Early thymocytes also proliferated in response to IL-4 and IL-7, corroborating with previous reports on the role of these cytokines in early Tcell d e v e l~p m e n t . '~.~~"~ Our data show the presence of a limited population of (Table 3 ). CD8+ cells induced the conversion of TN cell-derived TGFPl from latent to active form, leading us to postulate that the mature cell pool in the thymus may have a feedback control on the proliferation of early precursor (Fig 5) . Even though we feel most of the TGFP is made by CD2+ TN cells, we cannot rule out a contribution by other cell types such as thymic epithelial cells.
Recently, Takahama et a l l 3 reported the role of TGFP in murine CD4-CD8I0 cell differentiation into CD4+CD8+ thymocytes through a paracrine mechanism. This study did not address the effect of TGFP on human TN cell differentiation; however, it differs from the work of Takahama et all3 in that it shows an autocrine source for TGFP. Our data are supported by previous reports that point to the autocrine inhibitory effect of TGFP on and murine4' hematopoietic stem cells. In addition, by contrast to Takahama et we have reversed TN inhibition by antibody to TGFP, further supporting the direct involvement of this cytokine. However, our data do not exclude a role for paracrine TGFP on human TN cell proliferation.
TGFP is generally secreted in a latent formb composed of a homodimer of 105 kD of which the c-terminal 112 amino acids of each chain form the mature active 25-kD cytokines. In vitro, the release of active TGFP from latent complex can be facilitated by enzymatic or physicochemical treatment. 3.4.49 As in this study, it was previously reported that coculture of two cell types, pericytes and endothelial cells, produced active TGFP, whereas culture of either one alone would produce only the latent form?' Meanwhile, molecular mechanism(s) for TGFPl activation and the TGFPI-derived suppression of TN cell growth remain to be established. In various human cell lineages, TGFP is shown to inhibit the proliferation by delaying or arresting progression through the late portion of G1 Recent studies on the intracellular target for TGFP have demonstrated that it prevents the assembly of cyclin E-Cdk2 and subsequent accumulation of cyclin-E-associated kinase activity.53 TGFP may cause a general inhibition of cyclin-CDK interactions during G1 leading to the inhibition of retinoblastoma protein phosphorylati~n.".'~ In recent years, various reports point to the involvement of repressor genes in the regulation of hematopoietic cell de~eloprnent.~' Relatively high TGFPl levels produced by TN cells suggest a role for these genes in regulating early T-cell development. TGFPl may thus repress early T-cell proliferation until their entry into the thymus, where an appropriate microenvironment inactivates TGFP 1 and allows their proliferation. Data showed an enhancement of the in vitro proliferation of early hematopoietic precursor cells after the addition of antisense to TGFP during their cult~res.''~.~~ Accordingly, disregulation of continuous repression by TGFPl or overcoming its effects may thus lead to leukemic transformation of T-cell precursors. Such TGFPrelated function was recently suggested for the development of a case of human T-cell lymphomas6 and some nonhematopoietic t~m o r s . "~~~~~~ Experiments are now in progress to assay this hypothesis in acute T-cell leukemia patients.
